UVA  CENTER  FOR  DIABETES  TECHNOLOGY  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 Safety of the Tandem t:slim X 2 with Control-IQ 
Automated Insulin Delivery System in 
Preschoolers, age 2-6 Years Old 
Study Sponsor 
Marc D . Breton , Ph.D. 
U
niversity of Virginia 
Cent er for Diabetes Technology 
 Protocol Chair 
R.Paul Wadwa, MD
Barbara Davis Center
University of Colorado
Participating Institutions 
University of Virgini a, Charlottesvill e, Virginia 
Barbara Davis Center , University of Colorado , Colorado 
Stanford University, California 
[STUDY_ID_REMOVED]
Version Number: v1.3 
30-Aug-201920 
21 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 2 of 50 Key Roles  22 
 
Sponsor Chair / IDE Chair   
Name, degree  Marc D. Breton, Ph.D.  
Institution Name  University of Virginia, Center for Diabetes Technology  
  
Protocol Chair/Director   
Name, degree  R. Paul Wadwa, MD  
Institution Name  Barbara Davis Center, University of Colorado  
 23 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 3 of 50 Protocol Version History  24 
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.0 Marc Breton  Marc Breton   Original Protocol  
1.1 Mary Oliveri  Mary Oliveri  22-Aug-2019  FDA revisions  
• Exclusion criteria added: use of 
diluted insulin  
• A phone with the Dexcom Follow 
app will be near the child 
participant during the home 
study.  
• Participant Stopping Criteria 
redefined  
IRB revisions  
• Parent/child enrollment required 
since parent is completing 
questionnaire;  
• Questionnaire to occur after 
home use of equipment ; 
• Added Other Risks: Photographs 
taken by the study team may be 
shared at conference ; 
presentations, study brochures, 
or potential research donors  
• Revised ‘Timing of Event’ 
section;  
• Revisions  throughout  document  
to improve clarity  
1.2 Mary Oliveri  Mary Oliveri  29-Aug-2019  FDA revisions  
• Clarified exclusion criteria  
• Added SMBG pre -meal on day 1 
open -loop & every bedtime 
during At -Home use  
• Added caregivers  
• Physical activity restricted if 
CGM is below 90 mg/dL  
1.3 Mary Oliveri  Mary Oliveri  30-Aug-2019  FDA revisions  
• If > 1 serious hypoglycemia or > 
1 DKA event occurs, the study 
may be paused to determine a 
root cause prior to continuation of 
the study  
• Transition back  to personal  
insulin  pump will be completed 
under the supervision of a study 
MD 
25 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 4 of 50 Site Principal Investigator Statement of Compliance  26 
Protocol Title: Safety of the Tandem t:slim X2 with Control -IQ Automated Insulin Delivery 27 
System in Preschoolers, age 2 -6 Years Old . 28 
Protocol Version/Date: v1.0/ 30-Aug-2019  29 
I have read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 30 
my duties include ensuring the safety of the study participants e nrolled under my supervision.  It 31 
is understood that all information pertaining to the study will be held strictly confidential and that 32 
this confidentiality requirement applies to all study staff at this site.  33 
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as 34 
required by the following: United States (US) Code of Federal Regulations (CFR) applicable to 35 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 36 
CFR Part 812).  37 
As the  Principal Investigator, I will assure that no deviation from, or changes to the protocol 38 
will take place without prior agreement from the sponsor and documented approval from the 39 
Institutional Review Board (IRB), or other approved Ethics Committee, except  where necessary 40 
to eliminate an immediate hazard(s) to the trial participants.  41 
All key personnel (all individuals responsible for the design and conduct of this trial) have 42 
completed Human Participants Protection Training and Good Clinical Practice Traini ng.  Further, 43 
I agree to ensure that all staff members involved in the conduct of this study are informed about 44 
their obligations in meeting the above commitments.  45 
 46 
Investigator’s Signature __________________________________  Date: _____ / _____ / _____  47 
          dd mmm  yyyy  48 
Investigator’s Name: ________________________________  49 
Site Name:  _______________________________________   50 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 5 of 50 List of Abbreviations  51 
ABBREVIATION  DEFINITION  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CRF Case Report Form  
CGM Continuous Glucose Monitoring System  
CLC Closed -Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
CTR Control -to-Range  
DiAs Diabetes Assistant  
DKA Diabetic Ketoacidosis  
EC European Commission  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
ID Identification  
iDCL International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin -on-Board 
IQR Interquartile Range  
JDRF Juvenile Diabetes Research Foundation  
LGS  Low Glucose Suspend  
PLGS  Predictive Low Glucose Suspend  
POC Point -of-Care 
QA Quality Assurance  
QC Quality Control  
RBM Risk-Based Monitoring  
RCT  Randomized Control Trial  
SC Standard of Care group  
SD Standard Deviation  
SMBG  Self-Monitoring Blood  Glucose  
TDD Total Daily Dose  
UI User Interface  
  52 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 6 of 50 Table of Contents  53 
 54 
CHAPTER 1: BACKGROUND INFORMATION  ................................ ................................ ..............  11 55 
1.1 Introduction  ................................ ................................ ................................ ....................  11 56 
1.2 Study Object ive ................................ ................................ ................................ ..............  12 57 
1.3 Primary Specific Aim  ................................ ................................ ................................ ..... 14 58 
1.4 Secondary Specific Aims  ................................ ................................ ...............................  14 59 
1.5 Study Design  ................................ ................................ ................................ ..................  15 60 
CHAPTER 2: STUDY ENROLLMENT AND SCREENING  ................................ ...............................  17 61 
2.1 Participant Recruitment and Enrollment  ................................ ................................ ........  17 62 
2.2 Informed Consent and Authorization Procedures  ................................ ..........................  17 63 
2.3 Participant Inclusion Criteria  ................................ ................................ .........................  17 64 
2.4 Participant Exclusion Criteria  ................................ ................................ ........................  17 65 
2.5 Eligibility Screening Procedures  ................................ ................................ ....................  18 66 
CHAPTER 3: STUDY DEVICES  ................................ ................................ ................................ .... 20 67 
3.1 Insulin Pump  ................................ ................................ ................................ ..................  20 68 
3.2 Continuous G lucose Monitoring  ................................ ................................ ....................  20 69 
3.3 Blood Glucose Meter and Strips  ................................ ................................ ....................  20 70 
3.4 Ketone Meter and Strips  ................................ ................................ ................................ . 20 71 
3.5 Study Device Accountability Procedures  ................................ ................................ ....... 20 72 
CHAPTER 4: STUDY EQUIPMENT TRAINING  ................................ ................................ .............  21 73 
4.1 Insulin Pump Training  ................................ ................................ ................................ .... 21 74 
4.2 CGM Training  ................................ ................................ ................................ ................  22 75 
4.3 Blood Glucose and Ketone Testing  ................................ ................................ ................  23 76 
4.4 Optimization of Insulin Pump Settings  ................................ ................................ ..........  24 77 
CHAPTER 5: HOTEL ADMISSION PROCEDURES  ................................ ................................ ........  25 78 
5.1 General Admission Instructions  ................................ ................................ .....................  25 79 
5.2 Hotel Staffing Qualifications  ................................ ................................ .........................  25 80 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 7 of 50 5.3 Pre-Admission Check -in Visit  ................................ ................................ .......................  25 81 
5.4 Admission Check -In (times are approximate)  ................................ ...............................  26 82 
5.5 Study Procedures  ................................ ................................ ................................ ............  26 83 
5.6 Hotel Ad mission Schedule (times are approximate)  ................................ ......................  26 84 
5.7 Bolus Treatment  ................................ ................................ ................................ .............  27 85 
5.8 Meal Boluses  ................................ ................................ ................................ ..................  27 86 
5.9 Group Activi ties ................................ ................................ ................................ .............  27 87 
5.10  Procedures Related to Discharge  ................................ ................................ ....................  27 88 
CHAPTER 6: CONTROL -IQ AT HOME  ................................ ................................ .........................  28 89 
6.1 At-Home Use  ................................ ................................ ................................ ..................  28 90 
6.2 Meal Bolus  ................................ ................................ ................................ .....................  28 91 
6.3 Blood Glucose Checks  ................................ ................................ ................................ ... 28 92 
6.4 Activity  ................................ ................................ ................................ ...........................  28 93 
6.5 Caregivers  ................................ ................................ ................................ .......................  28 94 
6.6 Post-Study Check -in Visit  ................................ ................................ ..............................  28 95 
6.7 Questionnaire  ................................ ................................ ................................ .................  29 96 
CHAPTER 7: GLYCE MIC TREATMENT GUIDEL INES ................................ ................................ .. 30 97 
7.1 Hotel Admission Glycemic Guidelines  ................................ ................................ ..........  30 98 
7.2 At-Home Glycemic Guidelines  ................................ ................................ ......................  30 99 
CHAPTER 8: REMOTE MONITORING  ................................ ................................ .........................  32 100 
8.1 Hotel Admission Monitoring  ................................ ................................ .........................  32 101 
8.2 Home Monitoring  ................................ ................................ ................................ ...........  32 102 
CHAPTER 9: TESTING PROCEDURES  ................................ ................................ .........................  33 103 
9.1 Laboratory / Point of Care Testing  ................................ ................................ .................  33 104 
CHAPTER 10: RISKS ASSOCIATED WITH CLINICAL TRIAL  ................................ ......................  34 105 
10.1  Potential Risks and Benefits of the Investigational Device  ................................ ...........  34 106 
10.2  Potential Risks and Benefits of the Investigational Device  ................................ ...........  37 107 
10.3  General Considerations  ................................ ................................ ................................ .. 37 108 
CLINICAL PROTOCOL  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 8 of 50 CHAPTER 11: ADVERSE EVENTS , DEVICE ISSUES , AND STOPPING RULES  ..............................  39 109 
11.1  Adverse Events  ................................ ................................ ................................ ...............  39 110 
11.2  Reportable Device Issues  ................................ ................................ ...............................  43 111 
11.3  Timing of Event Reporting  ................................ ................................ ............................  43 112 
11.4  Stopping Criteria  ................................ ................................ ................................ ............  44 113 
11.5  Indep endent Safety Oversight  ................................ ................................ ........................  44 114 
CHAPTER 12: MISCELLANEOUS CONSIDERATIONS  ................................ ................................ .. 45 115 
12.1  Prohibited Medications, Treatments, and Procedures  ................................ ....................  45 116 
12.2  Participant Withdrawal  ................................ ................................ ................................ ... 45 117 
12.3  Confidentiality  ................................ ................................ ................................ ................  45 118 
CHAPTER 13: STATISTICAL CONSIDERATION  ................................ ................................ ..........  46 119 
13.1  Statistical and Analytical Plans  ................................ ................................ ......................  46 120 
13.2  Statistical Hypotheses  ................................ ................................ ................................ .... 46 121 
CHAPTER 14: DATA COLLECTION AND MONITORING  ................................ .............................  48 122 
14.1  Case Report Forms and Device Data  ................................ ................................ .............  48 123 
14.2  Study Records Retention  ................................ ................................ ................................  48 124 
14.3  Protocol Deviations  ................................ ................................ ................................ ........  48 125 
CHAPTER 15: ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ................................ .............  49 126 
15.1  Ethical Standard  ................................ ................................ ................................ .............  49 127 
15.2  Institu tional Review Boards  ................................ ................................ ...........................  49 128 
15.3  Informed Consent Process  ................................ ................................ ..............................  49 129 
130 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 9 of 50 Protocol Summary  131 
PARTICIPANT AREA  DESCRIPTION  
Title  Safety of the Tandem t:slim X2 with Control -IQ Automated Insulin Delivery 
System in Preschoolers, age 2-6 Years Old.  
Investigational Device  Tandem Control -IQ with G6 Continuous Glucose Monitor  
Objectives  To assess study the safety profile of the Tandem t:slim X2 with Control -IQ system 
in children with T1D aged 2 -6 years old under free living condition  
Study Design  A single -arm, multi -center, clinical study  
Number of Sites  3 independent clinical sites – sharing IDE and regulatory documentation only  
Endpoint  Number of subjects wi th less than 6% time below 70 mg/dL and less than 40% time 
above 180 mg/dL.  
Population  Key Inclusion Criteria  
 Age ≥ 2 and < 6 years old at the time of visit 1  
 Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at 
least 3 months and using insulin at the time of enrollment  
 Use of an insulin pump in the past 3 months  
 Use of Dexcom G6 for at least 11 out of the last 14 days  
Key Exclusion Criteria  
 Hypoglycemia induced seizure or loss of consciousness in the past 3 months  
 Concurrent use of any non -insulin glucose -lowering agent  
 A condition, which in the opinion of the investigator or designee, would put the 
participant or study at risk.  
Sample Size  Up to 15 participants  
Participant Duration  About 14 days  
Protocol Overview/Synopsis  48 hour hotel stay with 24/7 study team supervision followed by parental remote 
monitoring for 72 hours of at-home use  
  132 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 10 of 50 Study Visits and Procedures  Schedule  133 
  134 ` SCREENING  OPEN LOOP 
AT-HOME 
USE  PRE -
ADMISSION  
CHECK -IN HOTEL 
ADMISSION  CLOSED 
LOOP AT -
HOME USE  POST -
ADMISSION  
CHECK -IN 
DURATION  ABOUT 3 
HOURS   ABOUT 30 
MINUTES   ABOUT 48 
HOURS  ABOUT 72 
HOURS  ABOUT 30 
MINUTES  
COMMENT  SCREEN / 
ENROLL   PHONE, 
EMAIL, TEXT  HOTEL  HOME  PHONE, 
EMAIL, TEXT  
Informed Consent  X      
Eligibility Assessment  X      
Medical History  X      
HbA1c  X      
Physical Exam  X   X   
Vital Signs  X   X   
Equipment Training  X   X   
Use of Study Equipment   X X X X  
Blood Glucose & Ketone 
Measurement     X   
CGM Placement   X X    
Review diabetes 
management and AEs     X X X 
Review Medical Changes    X X   
Questionnaire     X   
Return study equipment       X 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 11 of 50 Chapter 1:  BACKGROUND INFORMATION  135 
1.1 Introductio n 136 
The Tandem X2 insulin pump with Control -IQ Technology is a third -generation closed -loop 137 
control (CLC) system retaining the same control algorithm that was initially tested by UVA’s DiAs 138 
system and then implemented in the inControl system. DiAs is described  in 13 IDEs (see IDEs 1 - 139 
12 and 14 in the list below) and inControl is described in IDEs G160097, G160181, G150240, 140 
G140169/S010. IDE 17 -20 below are specific to the implementation proposed here. For complete 141 
algorithmic and clinical background, we refer to  these IDEs and to a number of scientific 142 
publications that describe glycemic control outcomes and clinical impressions from the use of 143 
these systems (see list of 25 peer -reviewed papers and scientific presentations under Bibliography). 144 
Overall, this contr ol algorithm has been implemented in two mobile platforms (DiAs and 145 
inControl) and an embedded system (Tandem t:slim X2 with Control IQ) which have been tested 146 
in 35 clinical trials by over 700 adults and children with type 1 diabetes (T1D) for over 1,200, 000 147 
hours of use to date in the U.S. and overseas.  148 
As described above, this project is a result of a sequence of clinical trials that have tested 149 
extensivel y. The following 20 IDEs reflect this progress:  150 
1. IDE #G110095: Feasibility study of closed loop control in type 1 diabetes using heart 151 
rate monitoring as an exercise marker, approved 10/08/2011;  152 
2. IDE #G120032: Early feasibility (pilot) study of outpatient control -to-range; 3/2/2012;  153 
3. IDE #G120210: Early feasibility study 2 of outpatient control -to-range; 10/12/2012;  154 
4. IDE #G130118: DiAs control -to-range nocturnal closed -loop camp study; 6/19/2013;  155 
5. IDE #G130121: Optimizing closed -loop control of type 1 diabetes mellitus in 156 
adolescents; 6/19/2013;  157 
6. IDE# G130142:  Closed loop control in adolescents using hea rt rate as exercise 158 
indicator; 7/16/13;  159 
7. IDE #G130143: Early feasibility study of adaptive advisory/automated (AAA) control 160 
of type 1 diabetes; 7/19/2013;  161 
8. IDE #G140066:  Full day and night closed -loop with DiAs platform; 5/9/14.  162 
9. IDE #G140068: Unified Safety  System (USS) Virginia Closed Loop versus sensor 163 
augmented pump therapy overnight in type 1 diabetes; 5/14/2014;  164 
10. IDE #G140089: Outpatient control -to-range: Safety and efficacy with day -and-night 165 
in-home use; 6/6/2014;  166 
11. IDE #G140169: Unified Safety System (U SS) Virginia Closed -Loop versus Sensor 167 
Augmented Pump (SAP) therapy for hypoglycemia reduction in type 1 diabetes; 168 
10/3/2014.  169 
12. IDE #G150221: Reducing risks and improving glucose control during extended 170 
exercise in youth with T1DM: The AP Ski Camp; 11/09/201 5;  171 
13. IDE #G150240: Project Nightlight: Efficacy and system acceptance of dinner/night vs. 172 
24 hr closed loop control; 11/12/2015;  173 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 12 of 50 14. IDE #G160047: Closed -loop in school -age children 5 -8 years old using DiAs platform; 174 
03/29/2016;  175 
15. IDE #G160097: Clinical Acceptan ce of the Artificial Pancreas: The International 176 
Diabetes Closed -Loop (iDCL) Trial/Research Site Training Protocol; 06/03/16.  177 
16. IDE#G160181: PROTOCOL 1 for “Clinical Acceptance of the Artificial Pancreas: The 178 
International Diabetes Closed Loop (iDCL) Trial; 09/21/16  179 
17. IDE#G170267: Real -Time Monitoring and Glucose Control During Winter -Sport 180 
Exercise in Youth with Type 1 Diabetes: The AP Ski Camp Continued. 12/01/2017  181 
18. IDE#G180053: Protocol 3: Clinical Acceptance of the Artificial Pancreas (DCLP3)  182 
19. IDE#G180279: Sa fety and Efficacy of Initializing the Control -IQ Artificial Pancreas 183 
System Using Total Daily Insulin, 11/21/2018  184 
20. IDE#G180053/S008: Protocol 5: Clinical Acceptance of the Artificial Pancreas in 185 
Pediatrics. A Study of t:slim X2 with Control -IQ Technology, currently enrolling, 186 
12/17/2018  187 
1.2 Study Objective  188 
The closed -loop system, also called Artificial Pancreas (AP), modulates insulin infusion according 189 
to computed real -time needs. It has proven to be successful in maintaining blood glucose in 190 
euglycemic range s during the day and even more efficiently during overnight hours where it was 191 
shown that the system can keep glycemic values in the euglycemic range (70 -180 mg/dL) for 70% 192 
to 75% of the time.  193 
The biggest challenges for glycemic control in young children w ith diabetes are frequent meals 194 
and snacks as well as unpredictable activity/exercise routines. Meal variability has the benefit that 195 
meals are typically announced and quantified. Glucose control around exercise, on the other hand, 196 
is more complicated if t he patient doesn’t announce a change in activity level.  197 
Over the last 5 years, our teams have developed and tested different version of closed -loop systems 198 
and remote monitoring systems conducting clinical trials in summer and winter camp settings 199 
demonstr ating significantly improved glycemic control and hypoglycemia avoidance in young 200 
adult and pediatric patients with T1D.  201 
There is a new wearable version of a closed -loop control system that is proposed to be tested in 202 
this clinical trial.  The Closed -Loop  Control System contained in t -slim X2 with Control -IQ 203 
Technology that is described in Master File MAF -2032/A003. Control -IQ Technology is derived 204 
from inControl previously described in IDE# G160097, G160181, G150240 and G140169/S010. 205 
The CLC is an “artifi cial pancreas” (AP) application that uses advanced closed loop control 206 
algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The 207 
system modulates insulin to keep blood glucose in a targeted range. The system components 208 
include the t:slim X2 with Control -IQ Technology and the Dexcom CGM G6 (  Figure  1). 209 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 13 of 50  Figure 1: t:slim X2 with Control -IQ and DexCo m G6 system  210 
This clinical trial aims to demonstrate the safety of the Closed -Loop Control (CLC), also known 211 
as Artificial Pancreas (AP) named t:slim X2 with Control -IQ Technology and assess usability in a 212 
supervised setting for the treatment of type 1 diab etes (T1D) in young children (2 -6 years old). It 213 
is important to note that the system under study has been shown safe in efficacious in a large 214 
(N=168) RCT clinical trial in subjects 14 and up (results presented at ADA 2019), which 215 
Compared the system with  sensor -augmented pump therapy, CLC system (Control -IQ) use for 6 216 
months improved : 217 
 Time in target range 70 -180 mg/dL (+11%; p<0.0001)  218 
 HbA1c ( -0.33%; p=0.0014)  219 
 Mean Glucose by CGM ( -13 mg/dL; p<0.0001)  220 
 Hyperglycemia >180 mg/dL ( -10%; p<0.0001)  221 
 Hypoglycemia <70 mg/dL ( -0.88%; p<0.0001)  222 
 Hypoglycemia <54 mg/dL ( -0.10%; p=0.02)  223 
The same system is also currently the subject of a similar trial down to 6 years old (IDE#20 above).  224 
Finally, preliminary analysis of a clinical trial in France using the same system in prepubertal 225 
children (6 -10 yo) comparing 24/7 vs overnight use has shown very promising performances as 226 
well ( Table 1). 227 
Table 1: Interim analysis of FREELIFEKIDS AP (N=30 for 3 months)  228 
 Overall  
 CLC at night  CLC 24/7  Stats 
 baseline  CLC  baseline  CLC  base vs 
Tx Night vs 
24/7 
% time below 50mg/dL  0.4 ± 
0.3%  0.3 ± 
0.2%  0.5 ± 
0.7%  0.3 ± 
0.2%  ns ns 
% time below 54mg/dL  0.7 ± 
0.6%  0.6 ± 
0.3%  0.9 ± 1%  0.5 ± 
0.4%  0.081  ns 

CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 14 of 50 % time below 60mg/dL  1.5 ± 1%  1.1 ± 
0.5%  1.7 ± 
1.6%  1.1 ± 
0.8%  0.041  ns 
% time below 70 mg/dL  4.1 ± 
1.9%  2.8 ± 1%  3.9 ± 
2.8%  2.8 ± 
1.9%  0.006  ns 
% time between 70 -
140mg/dL  42 ± 8.6%  45.6 ± 
7.4%  37.9 ± 
8.2%  49.3 ± 
4.9%  <0.001  0.009  
% time between 70 -
180mg/dL  63.2 ± 
9.1%  67.5 ± 
6.5%  59.7 ± 
8.4%  71.8 ± 4%  <0.001  0.009  
% time above 180mg/dL  32.8 ± 
9.2%  29.6 ± 
6.7%  36.4 ± 
9.5%  25.4 ± 
4.8%  <0.001  0.010  
% time above 250mg/dL  9.6 ± 
4.3%  8.6 ± 
3.7%  11.8 ± 
5.6%  6.1 ± 
2.2%  0.001  0.010  
% time above 300mg/dL  2.8 ± 
1.7%  2.7 ± 
1.8%  3.9 ± 
3.7%  1.7 ± 1%  0.030  0.046  
   
     
Average CGM [mg/dL]  158.1 ± 
13.6 156.7 ± 
10.5 165.4 ± 
15.8 150.2 ± 
7.4 0.001  0.006  
We propose to use the Control -IQ S ystem during a supervised 48 hours hotel stay with planned 229 
activities and meals; in addition, child participants will continue to use the system for another 3 230 
days at home under the parent/guardian(s) supervision.  231 
1.3 Primary Specific Aim  232 
Study the safety profile of the Tandem t:slim X2 with Control -IQ System in children with type 1 233 
diabetes aged 2 -6 years old . 234 
1.4 Secondary Specific Aims  235 
 Assess the safety profile of the system at home under parental/legal guardian(s) 236 
supervision  237 
 Compare system performance to normative data from a 6 -12 years old c ohort  238 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 15 of 50 1.5 Study Design  239 
1.5.1 Purpose/Objectives of Clinical Study  240 
The purpose of this study is to demonstrate the safety and efficacy the Artificial Pancreas system 241 
(Tandem t:slim X2 with Control IQ Technology) in T1D participants , aged 2 -6 y.o .  242 
1.5.2 Study Participant s 243 
Approximately 15 participants  with Type 1 Diabetes Mellitus , currently managed with insulin 244 
pump therapy, will participate  in the trial for approximately 14 days. The study will be performed 245 
at the University of Virginia , Stanford University, and the Bar bara Davis Center at the University 246 
of Colorado. Children and a parent/guardian(s) will use the system  at home in Open Loop until the 247 
start of the Hotel Admission. The child participant will then use the Control -IQ System  during a 248 
~48 hours study hotel/house admission . The child participant will then use the Control -IQ System 249 
at home for  72 ho urs under parental supervision and remote monitoring by the study team.  250 
1.5.3 Clinical Sites  251 
Each clinical site will perform the trial inde pendently, seeking their own local IRB approval.   252 
 The University of Virginia -Center for Diabetes Technology  253 
 560 Ray Hunt Drive, Charlottesville VA 22903  254 
 255 
 Stanford University  256 
 300 Pasteur Dr ive, # S302, Palo Alto, CA 94304  257 
 258 
 Barbara Davis Center for Diabete s, University of Colorado Anschutz Medical Campus:  259 
 1775 Aurora C ourt, Aurora, CO 80045   260 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 16 of 50 1.5.4 Study Diagram  261 
 262 
 263 
  264 
Figure 2: Study Diagram  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 17 of 50 Chapter 2:  STUDY ENROLLMENT AND SCREENING  265 
2.1 Participant Recruitment and Enrollment  266 
Enrollment will proceed with the goal of completing 15 participants in this trial, approximately 5 267 
participants per clinical site.   268 
Enrollment at the University of Virginia will be defined as a parent/child dyad as the parent is 269 
completing the questionnai re at the conclusion of the study.  270 
Up to 25 participants may sign the consent form.  271 
2.2 Informed Consent and Authorization Procedures  272 
Consenting procedures and documentation is defined in section 15.3.  273 
2.3 Participant Inclusion Criteria  274 
Child participants must meet all of the following inclusion criteria in order to be eligible to 275 
participate in the study.  276 
 Age ≥ 2 and < 6 years old at the time of consent  277 
 Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least 3 months 278 
and using in sulin at the time of enrollment  279 
 Use of an insulin pump in the past 3 months  280 
 Use of Dexcom G6 for at l east 11 out of the last 14 days  281 
 Parent/guardian(s)  have familiarity with and use of carbohydrate ratios for meal bolus es 282 
 Living with one or more parent/ guardian knowledgeable about emergency procedures for 283 
severe hypoglycemia and able to contact eme rgency services and study staff  284 
 At least one parent/guardian is willing to stay with the child during the hotel/house  portion of 285 
the study  on the dates selected by the study team  286 
 Investigator has confidence that the parent/guardian (s) can successfully operate all study 287 
devices and is capa ble of adher ing to the protocol  288 
 Willingness to switch to lispro (Humalog) or aspart (Novolog) if not already, and to use no 289 
other insulin besides lispro (Humalog) or as part (Novolog) during the study  290 
 Total daily insulin dose (TDD) of at least 5 U/day  291 
 Willingness not to start any new non -insulin glucose -lowering agent  during the course of the 292 
trial 293 
 Child p articipant and parent/guardian(s) willingness to  participate in all training sess ions as 294 
directed by study staff  295 
 Willingness to discontinue non -Tandem t:slim insulin pumps  during the entire study  296 
 Willingness to wear a Dexcom G6 sensor during the entire study  297 
 An understanding and willingness to follow the pro tocol and sign informed consent  298 
 299 
2.4 Participant Exclusion Criteria  300 
Individuals meeting any of the following exclusio n criteria at baseline will be excluded from study 301 
participation.   302 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 18 of 50 
 Hypoglycemia induced seizure or loss of consciousness in the past 3 months  303 
 Diabetes Ketoacidosis in the past 3 months  304 
 Use of diluted insulin  305 
 Concurrent use of any non -insulin glucose -lower ing agent  306 
 Hemophilia or any other bleeding disorder  307 
 A condition, which in the opinion of the investigator or designee, would put the participant 308 
or study at risk.  These conditions may include:  309 
 Acute illness at the time of  the enrollment visit (fever of 10 1 or higher, vomiting, diarrhea)  310 
 Addison’s disease  311 
 Diagnosed at less than 1 year of age without positive antibodies  312 
 Decreased renal function  313 
 Cystic fibrosis  314 
 Other chronic conditions, such as an underlying seizure disorder  315 
 Participation in another pharmaceutical or device trial at the time of enrollment or during the 316 
study.  317 
 Having a family member(s) employed by Tandem Diabetes Care, Inc. or having a direct 318 
supervisor at place of employment who is also directly involved in c onducting the clinical 319 
trial (as a study investigator, coordinator, etc.); or having a first -degree relative who is 320 
directly involved in conducting the clinical trial.  321 
2.5 Eligibility Screening Procedures  322 
After informed consent has been signed, the child  participant will be evaluated for study inclusion 323 
and exclusion eligibility and do cument ed: 324 
 Demographics (date of birth, gender, race and ethnicity)  325 
 Medical history  326 
 Details of the diabetes history: duration of disease (number of years), diagnosis details, curre nt 327 
insulin pump model, history of CGM use, current treatment (including basal rates, 328 
carbohydrate ratios, insulin sensitivity factors, target glucose, average daily insulin, history 329 
of diabetic ketoacidosis, history of severe hypoglycemia, history of seizu res or loss of 330 
consciousness, and average number of blood tests performed daily).  331 
 Surgical history  332 
 Allergies  333 
 Medications and supplements  334 
 Short Physical examination  – A historical history and physical report within 52 weeks of 335 
screening  appointment  may be  used  336 
 Weight and height  337 
 Vital signs  338 
 Hemoglobin HbA1c assessment (blood draw or point of care per study physician discretion)  339 
– A historical lab value dated within the last 30 days from screening date may be used  340 
 Use of Dexcom G6 for at least 11 out of the  last 14 days  341 
 342 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 19 of 50 Once all results of the screening evaluations are available, a decision will be made to determine 343 
the subject’s eligibility for the study or if one or more part s of the screening will have to be 344 
repeated. If at the first screening or repeat screening an exclusionary condition is identified, the 345 
study subject will be excluded from participation in the study.  The participants will be  referred to 346 
their primary care physician as needed. Subjects may be re -screened at a later date if their clinic al 347 
situation changes at the discretion of the study physician during an acceptable timeline.  348 
Parent/guardian(s) will be instructed to contact the study team in the event of a febrile illness 349 
anytime during the study .   350 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 20 of 50 Chapter 3:  STUDY DEVICES  351 
3.1 Insulin Pump  352 
The study system will include the Tandem t:slim X2 with Control -IQ technology.  353 
3.2 Continuous Glucose Monitoring  354 
The study CGM will include Dexcom G6 transmitter and sensors.  The CGM sensor is viable for  355 
10 days.  356 
3.3 Blood Glucose Meter and Strips  357 
Blood glucose levels will  be measured using the Accu -Chek Guide blood glucose meter 358 
(glucometer).  The CGM device will be calibrated, if needed, using the study glucometer and  strips 359 
in accordance with the manufacturer’s labeling.  360 
3.4 Ketone Meter and Strips  361 
Blood ketone levels will b e measured using the Abbott Precision Xtra meter and strips in 362 
accordance with the manufacturer’s labeling.  The blood glucose meter component of the Precision 363 
Xtra device will not be used.  364 
3.5 Study Device Accountability Procedures  365 
Device serial numbers will be recorded and use of equipment will be tracked.   366 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 21 of 50 Chapter 4:  STUDY EQUIPMENT TRAINING  367 
Equipment training may begin immediately after screening eligibility has been met  or may be 368 
deferred for a maximum of 14 days but should not be less than 48 hours prior to the sta rt of the 369 
study  to allow for a CGM warmup period . The purpose of this training  is to introduce the study 370 
insulin pump and study CGM to the parent/guardian(s) and child participant.  371 
The subject’s insulin parameters will be programmed into their Tandem t:slim X2 with Control - 372 
IQ pump  by two research staff. Subjects will then switch to the study insulin pump. The subject’s 373 
personal pump and infusion site will be removed.  374 
At the conclusion of the study equipment training session, the child participant will use the system 375 
in pump only (open loop) configuration where no closed loop algorithms are activated until the 376 
start of the Hotel Admission.  377 
Child participants will have the insulin pump and sensor on them at all times. Parent/guardian(s) 378 
will monitor their chi ld using the Dexcom App. Parent/guardian(s) will also be required to carry 379 
the study glucometer and ketone meter with them at all times and must be within BLE connection 380 
distance of their child (same room) or equip the child with a Clarity enabled cellphon e. Study 381 
supplied phones will be available upon request.   382 
4.1 Insulin Pump Training  383 
Insulin pump training will include:  384 
 The parent/guardian(s) will be fully instructed on the study insulin pump. A qualified 385 
system trainer will conduct the training and in par ticular discuss differences from their 386 
home pump in important aspects such as calculation of insulin on board and correction 387 
boluses. Additional topics not limited to but may include: infusion site initiation, 388 
cartridge/priming procedures, setting up the p ump, charging the pump, navigation through 389 
menus, bolus procedures including stopping a bolus, etc.  390 
 The study team will assist the parent/guardian(s) in study pump infusion site initiation and 391 
will start the participant on the study pump. The study pump wi ll be programmed with the 392 
child participant’s usual basal rates and pump parameters. The child participant’s personal 393 
pump will be removed.  394 
 The parent/guardian(s) will be supervised with the study pump during at least one meal or 395 
snack bolus to ensure part icipant understanding of the pump features.  396 
 The parent/guardian(s) will be encouraged to review the literature provided with the pump 397 
and infusion sets after the training is completed. Infusion sets manufactured by Tandem 398 
will be provided to the study subj ect and a sample list is below and may be provided in 399 
different cannula lengths (e.g. 6mm or 9mm) and tubing lengths (e.g. 23 or 43 inch):  400 
 Tandem Autosoft Line  (e.g. Autosoft 30, Autosoft 90, Autosoft XC)  401 
 Tandem Varisoft  402 
 Tandem TruSteel  403 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 22 of 50 Insulin pump training specific to the Control -IQ Technology functions will include:  404 
 How to turn o n and off Control -IQ technology  405 
 How to understand when Control -IQ is incre asing or decreasing basal rates  406 
 How to administer a meal or correction bolus on the t:slim X2 with  Control -IQ system  407 
 How to enable the sleep function and set the sleep schedule  408 
 The participant will be assessed for understanding of the system interface and how to  react 409 
to safety/alert messages  410 
 The participant will be gi ven a User Guide as a reference  411 
4.1.1 Closed Loop Training  412 
The parent/guardian(s) will be instructed to how to use the system if insulin is delivered by any 413 
means other than the study  pump (e.g. injection of subcutaneous insulin via syringe in the event 414 
of infusion site failure). If insulin is d elivered by any means other than the study pump, the 415 
parent/guardian(s) will be instructed to turn off Control -IQ for approximately four hours.  416 
The parent/guardian(s) will be provided with contact information and will be asked to call the 417 
study clinical  staff during periods of illness with an elevated temperature >101.5 degrees 418 
Fahrenheit (38.6 degrees Celsius), periods of significant illness, or during periods of use of 419 
medications such as epinephrine for the emergency treatment of a severe allergic reacti on or 420 
asthma attack in addition to use of oral or injectable glucocorticoids to determine if closed -loop 421 
use should be temporarily discontinued.  422 
The parent/guardian(s) will also be asked to call the study clinical  staff for technical issues with 423 
t:slim X2 with Control -IQ. The study pump without Control -IQ activated and study CGM  (open 424 
loop mode) during periods of component disconnections or technical difficulties.  Study staff 425 
contact information will be provided to parent/guardian(s) to ask any questions t hey may have 426 
during the study.  427 
Upon completion of the t:slim X2 with Control -IQ training, study staff will document, using a 428 
checklist, that the participant is familiar with the function/feature and/or capable of performing 429 
each of the tasks specified.  430 
Parents/legal guardian(s) will be provided Glycemic Treatment Guidelines ( section  7.2) to use at 431 
home.  432 
4.2  CGM  Training  433 
A study CGM will be provided to all child participants at the training session. The 434 
parent/guardian(s) will be provided with CGM equipment  and instructed to use  the study CGM on 435 
a daily basis. Child participants have prior use of the CGM so re -training will be specific to the 436 
individual.  Training may include review of  study CGM in real -time to make management 437 
decisions and how to review the data after an upload (if needed) for retrospective review.  438 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 23 of 50 The child’s personal CGM will be discontinued. The parent/guardian(s) will be observed placing 439 
the sensor  and will learn/review how to access the CGM trace via the t:slim X2 with Control -IQ 440 
user interface. The parent/ guardian(s) will be instructed to perform a fingerstick blood glucose 441 
measurement prior to meal time for the first open -loop day. The parent/guardian(s) will be asked 442 
to perform fingerstick blood glucose measurements (if needed) in accordance with the labe ling of 443 
the study CGM device.  444 
The study CGM user’s guide will be provided for the parent/guardian(s) to take home. The study 445 
team will be sure that the parent/guardian(s) will leave the clinic knowing how to use proper use 446 
the CGM. The study team will be available for any questions.  447 
The use of Dexcom Apps on personal devices to monitor the child participant’s CGM values and 448 
alerts in  real-time may be used.  449 
Participants  will have the option of using their personal smartphone or receive a study smartphone 450 
to use in order to collect the data from the devices.  451 
4.3 Blood Glucose and Ketone Testing  452 
4.3.1 Blood glucose testing  453 
Parent/guardian(s) will be provided with a study blood glucose meter and test strips to be used at 454 
home per manufacturer guidelines.  455 
All study blood glucose meters will be QC tested by study staff with at least two different 456 
concentrations of control solution , if available.  A tested meter will not be used in a study if it does 457 
not read within the target range at each concentration per manufacturer labeling.   458 
Parent/guardian(s) will be reminded to use the study blood glucose meter for all fingerstick BGs 459 
during the study.  460 
4.3.2 Blood ketone testing  461 
Parent/guardian(s) will be provided with a study blood ketone meter and  test strips  to be used  at 462 
home per manufacturer guidelines.  463 
All study blood ketone meters will be QC tested  by study staff with at least two different 464 
concentrations of control solution, if available.  A tested meter will not be used in a study if it does 465 
not read within the ta rget range at each concentration per manufacturer labeling.   466 
Parents/legal guardian(s) will be instructed to perform blood ketone testing as described in 467 
Glycemic Treatment Guidelines (section 7.2). A home glucagon emergency kit  will be required . 468 
Participants who currently do not have one will be given a prescription for the glucagon emergency 469 
kit. 470 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 24 of 50 4.4 Optimization of Insulin Pump Settings  471 
Data -driven opti mization of pump settings can occur any time during the study, particularly if the 472 
parent/guardian(s) contacts the study physician due to concerns about their pump settings due to 473 
recurring hypo - or hyperglycemia.   474 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 25 of 50 Chapter 5:  HOTEL ADMISSION PROCEDURES  475 
5.1 General Admiss ion Instructions  476 
The Hotel Admission will t ake place in a hotel  or research house  for approximately 48 hours. 477 
Alternately, the clinical trial may occur at a house.  478 
The CGM used in the study is FDA -approved for the non -adjunctive measurement of blood 479 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will 480 
be the primary source of blood glucose levels.  There are no protocol finge rstick blood glucose 481 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 482 
team.  Glycemic Treatment Guidelines to be used during the hotel admission are defined in section 483 
7.1. 484 
5.2 Hotel Staffing Qualifications  485 
There will be at least one physician, advanced practice provider, registered nurse, and/or other 486 
medical personnel who are specifically trained in diabete s management and trained technicians 487 
supervising the Hotel Admission . Certification of their skill is supervised by the clinical site PI. 488 
All medical personnel who will have direct contact with the child participants will have current 489 
certification in Basi c Life Support including CPR. Study personnel, trained in the use and 490 
maintenance of the Tandem t:slim X2 with Control -IQ Technology , will be monitoring the system 491 
during the entire trial.  492 
There will be a team of at least 3 experienced study personnel in attendance during the day ( 7 p.m. 493 
-7 a.m .) and one study staff member during the overnight hours of 7 p.m.  – 7 a.m. during the hotel 494 
admission . These staff members will be proficient with devices, the study protocol and its 495 
procedures, including the glycem ic safety protocols.  496 
Glucagon for the emergency treatment of hypoglycemia will be available on -site. 497 
5.3 Pre-Admission Check -in Visit  498 
The parent/guardian(s) will be contacted by the study team approximately 48-72 hours  prior to the 499 
hotel admission  to verify the following information:  500 
 Inquire about any changes to the child participant’s health (e.g. illness, medications, etc…)  501 
 Inquire about current use of the study equipment  502 
 Remind parent/guardian(s) to bring all current medications for use during the study.  503 
 Determine what pump profile (s) the subject uses on certain days  504 
 Verify that a new CGM sensor will be placed approximately 48 hours  prior to the admission  505 
for proper warm up  506 
 Verify with the subject that the goal CGM reading at time of arrival is  less than 250 mg/dL   507 
Should any concerns regarding medical history, pump information, or unforeseen issues arise, the 508 
admission may be cancelled for that partic ipant at the  discretion of the investigator . 509 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 26 of 50 Additional phone contact(s) can occur at the study team’s discretion.  510 
5.4 Admission Check -In (times are approximate)  511 
On day 1 of the admission, parent/guardian(s) and child participants will arrive to the hotel at 512 
approximately 3 -5 pm. The study team will perform vital signs and inquire about any changes to 513 
the participant’s medical history.  The study team will confirm that the child participant has 514 
brought his/her insulin and regular me dications. Any changes to medical history will be 515 
communicated to the medical physician to ensure continued eligibility and participation. The study 516 
team will ensure the proper function of the CGM and insulin pump.  Insulin parameters will be 517 
reviewed by t he study medical team  518 
A SMBG and a ketone value will be collected on the study equipment. In the event that the child 519 
participant’s CGM reading is not between 80 – 300 mg/dL or ketone concentration is ≤0.6 mmol/L  520 
prior to the Control -IQ initiation, the study physician may recommend c orrective act ion as outlined 521 
in the Hotel Admission Glycemic Guidelines  (section 7.1). Study physician may elect to  cancel 522 
participant’s participation in the hotel admission  if concerned about their medical safety .   523 
Data from subjects’ insulin pumps will be reviewed and/or downloaded for a review of pump 524 
settings and average of daily insulin delivery.  525 
5.5 Study  Procedures  526 
Parent/guardian(s) will be retrained on the study equipment as needed. During system use, subjects 527 
will be remotely monitored and will hav e immediate access to medical personnel and technical 528 
personnel.  Child participants will be accompanied by at least one parent/ guardian  during the 529 
supervised stay and trained on the Control -IQ System . A trained parent/caregiver or study team 530 
member must r emain in the immediate vicinity of the subjects as long as the AP system is active.  531 
The parent/guardian(s)  will be primarily responsible for using the system at this time, with the 532 
study team serving as a back -up when needed. Re -education will be provided  as needed. Study 533 
staff will be available at all times to assure proper use of all study equipment.  534 
CGM sensors last up to 10 days ; therefore , there should be no need to change CGM sensors. All 535 
sensor changes during camp will be handled by the study team, but caregivers of subjects will be 536 
trained on how to change sensors in case of sensor failure during the 72 hours home use.  537 
5.6 Hotel Admission Schedule  (times are approximate)  538 
Parent/guardian(s) and child participants will be provided dinner at approximately 6 – 7 p.m. 539 
Parent/guardian(s) and child participants will be permitted to retire to their personal rooms after 540 
dinner, if desired.  Bedtime for the child participant is encouraged to be no later than 9 p.m. Devices 541 
should be charged overnight while subject s are sleeping.  542 
On day 2 of the a dmission, breakfast will be provided  at approximately 7 – 8 a.m. Group activities 543 
will occur  from approximately 9 – 11 a.m . An optional snack will be available at approximately 544 
10 a.m.  545 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 27 of 50 Lunch will be provided at approximat ely 11:30 – 12:30 p.m.  Parent/guardian(s) and child 546 
participants will retire to their personal rooms for quiet time. An optional snack will be available 547 
at approximately 3 p.m. Group activities will occur from approximately 3:30 – 5:30 p.m.  548 
Parent/guardian(s) and child par ticipants will be provided dinner at approximately 6 -7 p.m. 549 
Parent/guardian(s) and child participants will be permitted to retire to their personal rooms after 550 
dinner, if desired.  Bedtime for the child participant is encouraged to be no later than 9 p.m. Devices 551 
should be charged overnight while subjects are sleeping.  552 
On day 3 of the admission, breakfast will  be provided at approximately 7 – 8 a.m. Group activities 553 
will occur from approximately 9 – 11 a.m. An optional snack will be available at approximate ly 554 
10 a.m.  Lunch will be provided at approximately 11:30 – 12:30 p.m.   555 
Discharge will occur after lunch.   556 
5.7 Bolus Treatment  557 
Use of a temporary basal rate will be permitted during the hotel admission.  558 
5.8 Meal Boluses  559 
The time and size of the meal bolus will be determined by parent/guardian(s) and  will be  560 
supervised by the study team.      561 
5.9 Group Activities  562 
Planned group activities may be managed by the study team or a specialized service provider (e.g. 563 
preschool professionals) with study staff supervision. These activities may include transporting 564 
parent/guardian(s) and child participants to off -site locatio ns (e.g. museums, amusement parks, 565 
etc…).  One medical personnel per car will be required.  Parents and their children are expected to 566 
participate in all activities of the supervised phase, unless excused by the study team .  567 
5.10 Procedures Related to Discharge  568 
Parent/ guardian (s) will show proficiency of using the system before leaving for the home portion 569 
of the trial.  570 
Parent/ guardian (s) will show proficiency on how to change CGM before leaving for the home use 571 
portion of the trial.  572 
The child participant’s  SMB G value needs to be between  70-300 mg/dL and ketone concentration 573 
is ≤ 0.6 mmol/L prior to discharge. The parent/guardian(s) and  child will be offered a  snack prior 574 
to discharge.  The study team will verify that parent/guardian(s) have study team’s contact 575 
information.   576 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 28 of 50 Chapter 6:  CONTROL -IQ AT HOME  577 
6.1 At-Home Use  578 
Child participants will continue to use the Control -IQ System for another 72 hours at home under 579 
parental/legal guardian(s) supervision. The study team will continue remote monitoring as 580 
described in section  8.2. Study staff will be available 24/7 by phone to answer any questions or 581 
concerns or to help resolve any technical problems.  582 
At the conclusion of 72 hours, the parent/guardian(s) will remove the study equipment  under the 583 
supervision of a study physician  which may occur at home or in the presence of study staff. 584 
Participants who discontinue use of the study devices at home will return study devices by standard 585 
shipping (e.g. FedEx) provided by the research team.  586 
Parent/guardian(s) will be asked to download the child participant’s personal pump to ensure the 587 
child’s personal equipment is working properly.  588 
6.2 Meal Bolus  589 
Child participants may consume meals and snacks of their own choice with no restrictions. Meal 590 
size will be estimated by the pa rent/guardian(s). The timing of the bolus will be per each child 591 
participant’s typical dosing routine.  592 
6.3 Blood Glucose Checks  593 
Parent/guardian(s) will be advised to obtain their ch ild’s fingerstick blood glucose value prior to 594 
bedtime each night of at -home use.  595 
6.4 Activity  596 
The child should refrain from activity (e.g. sports) if their CGM value is below 90 mg/dL.  597 
6.5 Caregivers  598 
In the event that the child is in the care of someone other than the parent/guardian(s), the child 599 
must be routinely cared for by this individual (i.e. more than once per week for more than one 600 
month).  This individual must be trained on the use of the study devices and safety guidelines by 601 
study staff prior to the  child using the device at home.   602 
6.6 Post-Study  Check -in Visit  603 
Approximately 48 hours after t he home use of the equipment, the study team will contact  the 604 
parent/guardian(s) via phone/email/text to assess:  605 
 adverse events, adverse device effects, and device i ssues  606 
 blood glucose values <60 mg/dL and >300 mg/dL  607 
 verify collection of ketone measurement data  608 
 answer any questions related to device use  609 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 29 of 50  unscheduled calls during the study period may be recommended for additional device 610 
training or other unanticipated needs  611 
6.7 Questionnaire  612 
Parent/Guardian(s) will be asked to complete a Technology Acceptance Questionnaire (Parent 613 
Version) asking them their perceptions and feeling about the technology used during the Hotel 614 
Admission.    615 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 30 of 50 Chapter 7:  GLYCEMIC TREATMENT GU IDELINES  616 
7.1 Hotel Admission Glycemic Guidelines  617 
Upon arrival, the subject will be asked to check the CGM reading and ketone concentration using 618 
the study ketone meter.  If CGM is <70 mg/dL or > 300 mg/dL, or ketone test is >0.6 mmol/L, the 619 
study physician will suggest appro priate treatment.  The study team may request fingersticks as 620 
needed. The study subject may continue participation in the trial once CGM is between 70 -300 mg 621 
/dL and ketone concentration is ≤0.6 mmol/L.  622 
If CGM < 80 mg/dL during the day, the patient will be  treated until CGM reads >80 mg/dL. If 623 
CGM < 70 mg/dL during the night , hypoglycemia treatment will be provided until CGM reads > 624 
80 mg/dL. SMBG may be performed if the MD on -call deems it necessary.  625 
If CGM >300 mg/dL for more than 60 minutes, SMBG will b e performed every 60 minutes. If 626 
SMBG >300 mg/dL, the Glycemic Treatment Guidelines will be applied.  627 
If CGM <8 0 mg/dL at any time, subjects will be given approximately 16 grams of fast -acting 628 
rescue carbohydrates.  Study team will monitor CGM rise and will  consider treating again if CGM 629 
<80 mg/dL after approximately 20 minutes.  Hypoglycemic treatments can occur at any time per 630 
study physician request.  631 
Parent/guardian(s)  will be asked to respond to both hypoglycemia and hyperglycemia alarms 632 
during the Hotel  Admission.  If they do not respond to the alarms within 10 minutes, study 633 
personnel will assist as per the Glycemic Treatment Guidelines.  634 
Medical personnel and emergency supplies (e.g. glucagon) will be available on site.  635 
7.2 At-Home Glycemic Guidelines  636 
7.2.1 CGM Measurements  637 
CGM values are updated every 5 minutes and parents will be able to see it on the pump and 638 
Dexcom App.  639 
CGM alarms on the study team controlled Dexcom App will be set at 70 mg/dl for 30 minutes and 640 
300 mg/dl for 60 minutes.  641 
If CGM < 80 mg/dL dur ing the day, the patient will be treated until CGM reads >80 mg/dL. If 642 
CGM < 70 mg/dL during the night. Hypoglycemia treatment will be provided until CGM reads > 643 
80 mg/dL. SMBG may be performed if the MD on -call deems it necessary.  644 
If CGM >300 mg/dL for m ore than 60 minutes, SMBG will be performed every 60 minutes. If 645 
SMBG >300 mg/dL, the Glycemic Treatment Guidelines will be applied.  646 
A study team member will contact the family if either of the above conditions is triggered and 647 
confirm treatment per provid ed guidelines.  648 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 31 of 50 7.2.2 Ketone Measurements   649 
Parent/guardian(s) will be advised to test for ketones any time the CGM is above 300 mg/dL for 650 
more than 2 hours.  651 
If ketones are 0.6 -3.0 mmol/L , the following guidelines should be  followed until SMBG < 250 652 
mg/dL.  653 
 Notify MD as soon as possible  654 
 Consider taking correction dose of insulin by syringe or pen  655 
 Change insulin in reservoir and tubing and change pump site  656 
 Drink sugar -free beverages  657 
 Once BG is 100 -250 mg/dL, restart pump treatment in appropriate mode. Record t he 658 
amount of insulin that was given when prompted  659 
If ketones are >3.0 mmol/L, t he following guidelines s hould occur:  660 
 The participant will stop the study  661 
 Notify MD as soon as possible  662 
 Disconnect the STUDY insulin pump and start HOME insulin pump once instr ucted by 663 
MD 664 
 Take correction dose of insulin by syringe or pen  665 
 Drink sugar -free beverages   666 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 32 of 50 Chapter 8:  REMOTE MONITORING  667 
8.1 Hotel Admission Monitoring  668 
Parent/guardian(s) will remotely monitor the subjects in real -time using the DexCom G6 App 669 
capabilities provided by Dexco m Inc. during the Hotel Admission.   670 
Staff will remotely monitor the subjects in real -time using the DexCom G6 capabilities provided 671 
by Dexcom  Inc. . Notification will be set for CGM readings below 80mg/dl during the day and 672 
70mg/dl at night or above 250mg/dl  to alert study staff of the need treatment or SMBG 673 
confirmation. In case of remote monitoring failure, CGM alarms will be activated at low=70 674 
mg/dL and high=250 mg/dL for the study personnel to act if alarms are set off.  675 
8.2 Home Monitoring  676 
Parent/gua rdian(s) will remotely monitor the subjects in real -time using the DexCom G6 App 677 
capabilities provided by Dexcom  Inc. Alerts will be setup for values below 70mg/dL and above 678 
250mg/dL; families may choose to use more conservative thresholds (i.e. higher th an 70 and/or 679 
lower than 250) as well as supplemental alerts.  680 
Additionally, a smart phone with the Dexcom Share app will always be in the vicinity of the child 681 
during the home study.  This app may be on a parent’s phone or the study team will provide a 682 
phon e that will be used with parents or caretakers.  683 
In addition, the study staff will include the staff remote monitoring for threshold alerts but with 684 
alerts adapted to the existence of a first tier remote monitor ( parent/legal guardian(s) ) and the fact 685 
that they are not one site. Therefore, the study staff (Tier 2) alerts will be <70mg/dL for more than 686 
15 minutes and >300 mg/dL for more than 60 minutes.   687 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 33 of 50 Chapter 9:    TESTING PROCEDURES  688 
9.1 Laboratory / Point of Care Testing  689 
9.1.1 HbA1c  690 
 Performed locally at the Screening visit. Blood test may be obtained within 30 days  prior 691 
to enrollment.  692 
 HbA1c level will be measured using the DCA Vantage Analyzer , a comparable point of 693 
care device or local laboratory  694 
  695 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 34 of 50 Chapter 10:    RISKS ASSOCIATED WITH CLINICAL TRIAL  696 
10.1 Potential Risks and Benefits of the Investigational Device  697 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 698 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are alway s a 699 
risk in participants with type 1 diabetes and participants will be monitored for these symptoms.  700 
10.1.1  Known Potential Risks  701 
10.1.1.1  Venipuncture Risks  702 
A hollow needle/plastic tube will be placed in the arm for taking blood samples. Blood draws can 703 
cause some commo n reactions like pain, bruising, or redness at the sampling site.  Less common 704 
reactions include bleeding from the sampling site, formation of a small blood clot or swelling of 705 
the vein and surrounding tissues, and fainting.  706 
10.1.1.2  Fingerstick Risks  707 
About 1 drop of blood will be removed by fingerstick for measuring blood sugars and sometimes 708 
HbA1c or other tests. This is a standard method used to obtain blood for routine hospital laboratory 709 
tests.  Pain is common at the time of lancing.  In about 1 in 10 cases, a small amount of bleeding 710 
under the skin will produce a bruise.  A small scar may persist for several weeks.  The risk of local 711 
infection is less than 1 in 1000.  This should not be a significant contributor to risks in this study 712 
as finger sticks are part of the usual care for people with diabetes.  713 
10.1.1.3  Subcutaneous Catheter Risks (CGM)  714 
Participants using the CGM will be at low risk for developing a local skin infection at the site of 715 
the sensor needle placement.  If a catheter is left under the skin for more th an 24 hours it is possible 716 
to get an infection where it goes into the skin, with swelling, redness and pain.  There may be 717 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk).  718 
Study staff should verbally alert t he participant that on rare occasions, the CGM may break and 719 
leave a small portion of the sensor under the skin that may cause redness, swelling, or pain at the 720 
insertion site.  The participant should be further instructed to notify the study coordinator 721 
immediately if this occurs.  722 
10.1.1.4  Risk of Hypoglycemia  723 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 724 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less 725 
than it would  be as part of daily living.  Symptoms of hypoglycemia can include sweating, 726 
jitteriness, and not feeling well.  Just as at home, there is the possibility of fainting or seizures 727 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 728 
hypoglycemia.  A CGM functioning poorly and significantly over -reading glucose values could 729 
lead to inappropriate insulin delivery.  730 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 35 of 50 10.1.1.5  Risk of Hyperglycemia  731 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for  an 732 
extended period or if the pump or infusion set is not working properly.  A CGM functioning poorly 733 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin 734 
delivery.  735 
10.1.1.6  Risk of Device Reuse  736 
The study CGM system is la beled for single use only. The sensor (the component of the system 737 
that enters the skin) will be single use only. The transmitter and receiver may be reused during the 738 
study after cleaning the device using a hospital -approved cleaning procedure. The transm itter is 739 
attached to the sensor but does not enter the skin and the receiver , if used,  is a hand held device. 740 
Participants will be informed that FDA or relevant national authorities have approved these devices 741 
for single use and that by using them among mu ltiple patients, bloodborne pathogens (i.e. Hepatitis 742 
B) may be spread through the use of multiple users.  743 
The study insulin pump is labeled for single -patient use. During the study, this device may be 744 
reused after cleaning adhering to a hospital -approved c leaning procedure. All infusion set 745 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.)  746 
Participants will be informed that FDA or relevant national authorities typically approve the insulin 747 
pump device for sing le use and that by using them among multiple patients, bloodborne pathogens 748 
(i.e. Hepatitis B) may be spread through the use of multiple users.  749 
The study blood glucose meter and blood ketone meter are labeled for single -patient use. 750 
During  the study, these  devices may be reused after cleaning adhering to a hospital -approved 751 
cleaning procedure.  Participants will be informed that FDA or relevant national authorities 752 
typically approve the glucose and ketone meters for single use and that by using them among 753 
multiple patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of 754 
multiple users.  755 
10.1.1.7  Device Cleaning Instructions  756 
CGM cleaning instructions are provided in the Dexcom G4 PLATINUM (Professional) Cleaning 757 
and Disinfection manual (current edition). The transmitter should be cleaned with Clorox 758 
Healthcare® Bleach Germicidal Cleaner or any disinfectant product in a spray b ottle containing a 759 
bleach solution of 6500 parts per million with the EPA registration number 56392 -7.  The 760 
transmitter will be submerged in this solution and then placed on an absorbent wipe or clean 761 
surface.  Two sprays will be dispensed from the Clorox cleaner onto each side of the transmitter. 762 
A nylon brush will be used to scrub the transmitter on all sides for 30 seconds.  The transmitter 763 
will be placed in the Clorox Cleaner solution for one minute. Transmitter is then rinsed under 764 
flowing tap water fo r ten seconds. The transmitter will then be disinfected using a disinfectant 765 
product with EPA registration number 56392 -7 using similar procedures as the cleaning process.   766 
Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 767 
household or industrial cleaners, sol vents, bleach, scouring pads, chemi cals, or sharp instruments 768 
are prohibited. The pump should never be submerged in water. If needed, use only a very mild 769 
detergent, such as a bit of liq uid soap with wa rm water. A soft towel will be used to dry the pump. 770 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 36 of 50 The outside of the transmitter will be wiped with a damp lint -free cloth or isopropyl alco hol wipe 771 
between uses.  772 
The Accu -Chek Guide glucometer is cleaned and disinfected with two separate Super Sani -Cloths 773 
(EPA number 9480 -4). The entire surface will be cleaned, making sure the surface stays wet for 2 774 
minutes. This step is repeated with a clean cloth for disinfecting the device.  775 
The Precision Xtra User’s Guide suggests that healthcare professionals us e 10% bleach, 70% 776 
alcohol or 10% ammonia to clean the device.  777 
Equipment that touches intact skin will be cleaned with ethyl or isopropyl alcohol (70 -90%), 778 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number 46781) or household 779 
bleach. The contact time on the surface depends on the method used to clean the equipment. 780 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 781 
require two minutes on the equipment. The surface should remain wet (i.e. slightl y damp) with the 782 
disinfectant to be considered effective though not wet enough to leave drops of liquid.  783 
In the event a manufacturer updates cleaning procedures for their device, the study team will 784 
adhere to the most current recommendations.  785 
There is th e risk of blood sampling collection and contamination from sampling techniques. Hand 786 
washing with either soap & water or waterless hand sanitizer will be used prior to caring for the 787 
study subject. Gloves will be worn during blood sample collection and pro cessing. Medical 788 
personnel will continue to practice hygiene for the subject’s protection (i.e. hand washing, 789 
changing gloves frequently, disposing needles properly). Gloves will be removed and hands 790 
washed prior to leaving and upon return to the subject’s  room. Soiled linen will be changed to 791 
minimize the transfer of pathogenic organisms.  792 
10.1.1.8  Hb1Ac Risk  793 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) will be utilized at the research site 794 
to obtain the subject’s HbA1c level.  795 
10.1.1.9  Questionnaire  796 
As part of the study, parent/guardian(s)  will complete a Technology Acceptance Questionnaire 797 
which includes questions about their private attitudes, feelings and behavior related to t:slim X2 798 
with Control -IQ.  It is possible that some people may find these questionna ires to be mildly 799 
upsetting. Similar questionnaires have been used in previous research and these types of reactions 800 
have been uncommon.  801 
10.1.1.10  Other Risks  802 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 803 
the CGM , or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  804 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 805 
etc.) will be tried, sites will be rotated frequently, and a mild t opical steroid cream or other 806 
medication may be required.  807 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 37 of 50 Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 808 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 809 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 810 
topical antibiotics can be used.  The risk of skin problems could be greater if you use a sensor for 811 
longer than it is supposed to be used.  Therefore, parti cipants will be carefully instructed about 812 
proper use of the sensor.  813 
Data downloaded from the CGM, pump, and glucose and ketone meter will be collected for the 814 
study as measures of diabetes self -management behaviors.  Some people may  be uncomfortable 815 
with the researchers' having such detailed information about their daily diabetes habits.  816 
The Hotel Admission will have other parents and child participants in attendance. The loss of 817 
privacy and confidentiality is a likely risk as the study team is not able to  restrict other 818 
participants from sharing photographs (i.e. social media).  Photographs taken by the study team 819 
may be shared at conference presentations, study brochures, or potential research donors.  820 
10.1.2  Known Potential Benefits  821 
It is expected that this prot ocol will yield increased knowledge about using an automated 822 
closed -loop system with anticipatory action to control glucose levels.  The individual participant 823 
may not benefit from study participation.  824 
10.1.3  Risk Assessment  825 
Based on the facts that (1) adults and  adolescents with diabetes experience mild hypoglycemia and 826 
hyperglycemia frequently as a consequence of the disease and its management, (2) the study 827 
intervention involves periodic automated insulin dosing that may increase the likelihood of 828 
hypoglycemia,  and periodic automated attenuation of insulin delivery that may increase the 829 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested in prior studies 830 
using the investigational device system in the home setting, that limit the likel ihood of excessive 831 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and 832 
hyperglycemia can be achieved, it is the assessment of the investigators that this protocol falls 833 
under DHHS 46.405 which is a minor increase o ver minimal risk. In addition, it is the belief of the 834 
investigators that this study also presents prospect of direct benefit to the participants and general 835 
benefit to others with diabetes.  836 
10.2 Potential Risks and Benefits of the Investigational Device  837 
Risks and benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 838 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 839 
risk in participants with type 1 diabetes and participants will be  monitored for these events.  840 
10.3 General Considerations  841 
The study is being conducted in compliance with the policies described in the study policies 842 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with the 843 
protocol described herein, and with the standards of Good Clinical Practice (GCP).  844 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 38 of 50 Whenever possible, data will be directly collected in electronic case report forms, which will be 845 
considered the source data.  846 
The protocol is considered a significant risk device stu dy, due to the fact that the closed loop 847 
system is experimental.  Therefore, an investigational device exemption (IDE) from the U.S. Food 848 
and Drug Administration (FDA) is required to conduct the study.   849 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 39 of 50 Chapter 11:    ADVERSE EVENTS , DEVICE ISSUES , AND STOPPING RULES  850 
11.1 Adverse Events  851 
11.1.1  Definitions  852 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 853 
relationship between the adverse event and the device(s) under investigation ( section 11.1.2 ) for 854 
reportable adverse events for this protocol).  855 
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  856 
 Results in death.  857 
 Is life -threatening; (a non -life-threatening event whi ch, had it been more severe, might 858 
have become life -threatening, is not necessarily considered a serious adverse event).  859 
 Requires inpatient hospitalization or prolongation of existing hospitalization.  860 
 Results in persistent or significant disability/incapac ity or substantial disruption of the 861 
ability to conduct normal life functions (sight threatening).  862 
 Is a congenital anomaly or birth defect.  863 
 Is considered a significant medical event by the investigator based on medical judgment 864 
(e.g., may jeopardize the pa rticipant or may require medical/surgical intervention to 865 
prevent one of the outcomes listed above).  866 
Unanticipated Adverse Device Effect (UADE):  Any serious adverse effect on health or safety or 867 
any life -threatening problem or death caused by, or associate d with, a device, if that effect, 868 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 869 
investigational plan or application (including a supplementary plan or application), or any other 870 
unanticipated serious pro blem associated with a device that relates to the rights, safety, or welfare 871 
of participants (21 CFR 812.3(s)).  872 
Adverse Device Effect (ADE):  Any untoward medical occurrence in a study participant which the 873 
device may have caused or to which the device may have contributed (Note that an Adverse Event 874 
Form is to be completed in addition to a Device Deficiency or Issue Form).  875 
Device Complaints and Malfunctions:  A device complication or complaint is something that 876 
happens to a device or related to device perfor mance, whereas an adverse event happens to a 877 
participant.  A device complaint may occur independently from an AE, or along with an AE.  878 
An AE may occur without a device complaint or there may be an AE related to a device complaint.  879 
A device malfunction is  any failure of a device to meet its performance specifications or otherwise 880 
perform as intended.  Performance specifications include all claims made in the labeling for the 881 
device.  The intended performance of a device refers to the intended use for which  the device is 882 
labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites will  not be asked to 883 
distinguish between device complaints and malfunctions.  884 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 40 of 50 11.1.2  Reportable Adverse Events  885 
For this protocol, a reportable adverse event includes any untow ard medical occurrence that meets 886 
one of the following criteria:  887 
a. A serious adverse event  888 
b. An Adverse Device Effect as defined in section  11.1, unless excluded from r eporting in 889 
section 11.2 890 
c. An Adverse Event occurring in association with a study procedure  891 
d. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  892 
e. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a hyperglycemic 893 
or ketosis event meeting the criteria defined below  894 
Hypoglycemia and hyperglycemia not meeti ng the criteria below will not be recorded as adverse 895 
events unless associated with an Adverse Device Effect.  Skin reactions from sensor placement are 896 
only reportable if severe and/or required treatment.  897 
11.1.2.1  Hypoglycemic Events  898 
Hypoglycemia not associated wit h an Adverse Device Effect is only reportable as an adverse event 899 
when the following definition for severe hypoglycemia is met:  the event required assistance of 900 
another person due to altered consciousness, and required another person to actively administe r 901 
carbohydrate, glucagon, or other resuscitative actions.  This means that the participant was 902 
impaired cognitively to the point that he/she was unable to treat himself/herself, was unable to 903 
verbalize his/ her needs, was incoherent, disoriented, and/or co mbative, or experienced seizure or 904 
coma.  These episodes may be associated with sufficient neuroglycopenia to induce seizure or 905 
coma.  If plasma glucose measurements are not available during such an event, neurological 906 
recovery attributable to the restorat ion of plasma glucose to normal is considered sufficient 907 
evidence that the event was induced by a low plasma glucose concentration.  908 
11.1.2.2  Hyperglycemic Events/Diabetic Ketoacidosis  909 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 910 
event when one of the following 4 criteria is met:  911 
 the event involved DKA, as defined by the Diabetes Control and Complications Trial 912 
(DCCT) and described below  913 
 evaluation or treatment was obtained at a health care provider facility for an acut e event 914 
involving hyperglycemia or ketosis  915 
 blood ketone level ≥1.5 mmol/L and communication occurred with a health care provider 916 
at the time of the event  917 
 blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 918 
provider  919 
Hypergl ycemic events are classified as DKA if the following are present:  920 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 41 of 50  Symptoms such as polyuria, polydipsia, nausea, or vomiting;  921 
 Serum ketones ≥1.5 mmol/L or large/moderate urine ketones;  922 
 Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and  923 
 Treatment provided in a health care facility  924 
All reportable Adverse Events —whether volunteered by the participant, discovered by study 925 
personnel during questioning, or detected through physical examination, laboratory test, or other 926 
means —will be reported on an adverse event form online.  Each adverse event form is reviewed 927 
by the Medical Monitor to verify the coding and the reporting that is required.  928 
11.1.3  Relationship of Adverse Event to Study Device  929 
The study investigator will assess the relationship  of any adverse event to be related or unrelated 930 
by determining if there is a reasonable possibility that the adverse event may have been caused by 931 
the study device.  932 
To ensure consistency of adverse event causality assessments, investigators should apply t he 933 
following general guideline when determining whether an adverse event is related:  934 
Yes 935 
There is a plausible temporal relationship between the onset of the adverse event and the study 936 
intervention, and the adverse event cannot be readily explained by the participant’s clinical state, 937 
intercurrent illness, or concomitant therapies; and/or the adverse event follows a known pattern of 938 
response to the study intervention; and/or the adverse event abates or resolves upon discontinuation 939 
of the study intervention  or dose reduction and, if applicable, reappears upon re -challenge.  940 
No 941 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 942 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 943 
medication); and/or the adverse event has no plausible temporal relationship to study intervention.  944 
11.1.4  Intensity of Adverse Event  945 
The intensity of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, or (3) 946 
severe.  It is emphasized t hat the term severe is a measure of intensity: thus, a severe adverse event 947 
is not necessarily serious.  For example, itching for several days may be rated as severe, but may 948 
not be clinically serious.  949 
 MILD: Usually transient, requires no special treatment , and does not interfere with the 950 
participant’s daily activities.  951 
 MODERATE: Usually causes a low level of inconvenience or concern to the participant 952 
and may interfere with daily activities, but is usually ameliorated by simple therapeutic 953 
measures.  954 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 42 of 50  SEVERE : Interrupts a participant’s usual daily activities and generally requires systemic 955 
drug therapy or other treatment.  956 
11.1.5  Coding of Adverse Events  957 
The Medical Monitor will review the investigator’s assessment of causality and may agree or 958 
disagree.  Both the in vestigator’s and Medical Monitor’s assessments will be recorded.  The 959 
Medical Monitor will have the final say in determining the causality.  960 
Adverse events that continue after the participant’s discontinuation or completion of the study will 961 
be followed unt il their medical outcome is determined or until no further change in the condition 962 
is expected.  963 
11.1.6  Outcome of Adverse Event  964 
The outcome of each reportable adverse event will be classified by the investigator as follows:  965 
 RECOVERED/RESOLVED – The participant re covered from the AE/SAE without 966 
sequelae.  Record the AE/SAE stop date.  967 
 RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized 968 
without change in the event anticipated.  Record the AE/SAE stop date.  969 
 FATAL – A fatal outcome is defined as t he SAE that resulted in death.  Only the event that 970 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the 971 
time of death; however, were not the cause of death, will be recorded as “resolved” at the 972 
time of death.  973 
 NOT RECOVER ED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined 974 
as the event was ongoing with an undetermined outcome.  975 
 An ongoing outcome will require follow -up by the site in order to determine the final 976 
outcome of the AE/SAE.  977 
 The outcome of an ongoing event at the time of death that was not the cause of death, will 978 
be updated and recorded as “resolved” with the date of death recorded as the stop date.  979 
 UNKNOWN – An unknown outcome is defined as an inability to access the participant or 980 
the participant’s records t o determine the outcome (for example, a participant that was lost 981 
to follow -up). 982 
All clinically significant abnormalities of clinical laboratory measurements or adverse events 983 
occurring during the study and continuing at study termination should be followe d by the 984 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the 985 
underlying cause, or resolution.  Follow -up information should be recorded on source documents.  986 
If any reported adverse events are present when a par ticipant completes the study, or if a participant 987 
is withdrawn from the study due to an adverse event, the participant will be contacted for re - 988 
evaluation within 2 weeks.  If the adverse event has not resolved, additional follow -up will be 989 
performed as app ropriate.  Every effort should be made by the Investigator or delegate to contact 990 
the participant until the adverse event has resolved or stabilized.  991 
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 43 of 50 11.2 Reportable Device Issues  992 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irre spective of 993 
whether an adverse event occurred, except in the following circumstances.  994 
The following device issues are anticipated and will not be reported on a Device Issue Form but 995 
will reported as an Adverse Event if the criteria for AE reporting describ ed above are met:  996 
 Component disconnections  997 
 CGM sensors lasting fewer than the number of days expected per CGM labeling  998 
 CGM tape adherence issues  999 
 Pump infusion set occlusion not leading to ketosis  1000  
 Battery lifespan deficiency due to inadequate charging or extensive wireless 1001  
communication  1002  
 Intermittent device component disconnections/communication failures not leading to 1003  
system replacement  1004  
 Device issues clearly addressed in the user guide manual that do not require additional 1005  
troubleshooting  1006  
 Skin reactions fr om CGM sensor placement or pump infusion set placement that do not 1007  
meet criteria for AE reporting  1008  
11.3 Timing of Event Reporting  1009  
UADEs must be reported to the FDA by the IDE Sponsor within 10 working days of the study 1010  
team being notified of the event.  1011  
Other re portable adverse events, device malfunctions (with or without an adverse event), and 1012  
device complaints should be reported promptly by completion of an electronic case report form, 1013  
but there is no formal required reporting period.  1014  
Clinical sites  will notify  the IDE Sponsor  of any adverse event that is serious, related, and 1015  
unexpected. Notification will be made within 10 days after becoming aware of the event  in order 1016  
to adhere to FDA regulations.  1017  
Each principal investigator is responsible for reporting seri ous study -related adverse events and 1018  
abiding by any other reporting requirements specific to his/her Institutional Review Board or 1019  
Ethics Committee.  1020  
Upon receipt of a UADE report, the Sponsor will investigate the UADE and if indicated, report 1021  
the results o f the investigation to the sites’ IRBs, and the FDA within 10 working days of the 1022  
Sponsor becoming aware of the UADE per 21CFR 812.46(b) (2). The Medical Monitor must 1023  
determine if the UADE presents an unreasonable risk to participants. If so, the Medical M onitor 1024  
must ensure that all investigations, or parts of investigations presenting that risk, are terminated as 1025  
soon as possible but no later than 5 working  days after the Medical Monitor makes this 1026  
determination and no later than 15 working  days after firs t receipt notice of the UADE.  1027  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 44 of 50 In the case of a device system component malfunction (e.g. pump, CGM, control algorithm), 1028  
information will be forwarded to the responsible company by the site personnel, to be handled 1029  
by its complaint management system.  1030  
11.4 Stoppi ng Criteria  1031  
11.4.1  Participant Discontinuation of Study Device  1032  
Rules for discontinuing study device use are described below.  1033  
 The investigator believes it is unsafe for the participant to continue on the intervention.  1034  
This could be due to the development of a new  medical condition or worsening of an 1035  
existing condition; or participant behavior contrary to the indications for use of the device 1036  
that imposes on the participant’s safety  1037  
 The participant requests that the treatment be stopped  1038  
 One distinct episode of DKA  1039  
 One distinct severe hypoglycemia event as defined in section 11.1.2. 1 1040  
11.4.2  Criteria for Suspending or Stopping Overall Study  1041  
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1042  
hyperglycemia event (as defined in section 11.1.2.2 ), use of the study  device system will be 1043  
suspended while the problem is diagnosed.  1044  
If more than 1 serious hypoglycemia or more than 1 DKA event occurs, the study may be paused 1045  
to determine a root cause prior to continuation of the study.  1046  
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1047  
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1048  
study activities may resume if the underlying problem can be corrected by a protocol or syste m 1049  
modification that will not invalidate the results obtained prior to suspension. The study Medical 1050  
Monitor will review all adverse events and adverse device events that are reported during the study 1051  
and will review compiled safety data at periodic interva ls (generally timed to the review of 1052  
compiled safety data by the DSMB). The Medical Monitor may request suspension of study 1053  
activities or stoppage of the study if deemed necessary based on the totality of safety data available.  1054  
11.5 Independent Safety Oversight  1055  
A Medical Monitor will review all DKA and severe hypoglycemia irrespective of relatedness to 1056  
study device use, and all serious events (including UADEs) related to study device use at the time 1057  
of occurrence. The Medical Monit or also will be informed of any ADEs not meeting criteria for a 1058  
UADE. 1059  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 45 of 50 Chapter 12:    MISCELLANEOUS CONSIDERATIONS  1060  
12.1 Prohibited Medications, Treatments, and Procedures  1061  
Child participants  using glulisine at the time of enrollment will be asked to contact their personal 1062  
physician to change their prescribed personal insulin to lispro or aspart for the duration of the trial.  1063  
The study devices (study insulin pump, study CGM)  must be removed before Magnetic Resonance 1064  
Imaging (MRI), Computed Tomography (CT) or diathermy treatmen t. Participants may continue 1065  
in the trial after temporarily discontinuing use if requiring one of the treatments above.  1066  
12.2 Participant Withdrawal  1067  
Participation in the study is voluntary, and a participant may withdraw at any time.  For  participants 1068  
who withdr aw, their data will be used up until the time of withdrawal.  1069  
12.3 Confidentiality  1070  
For security and confidentiality purposes, subjects will be assigned an identifier that will be used 1071  
instead of their name.  Protected health info rmation gathered for this study may be shared with the 1072  
third party collaborators.  De -identified subject information may also be provided to collaborators 1073  
involved in the study after the appropriate research agreement has been executed.   1074  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 46 of 50 Chapter 13:    STATISTICAL CONSIDERATION  1075  
13.1 Statistical and Analy tical Plans  1076  
This trial is single -armed and not powered to detect differences between groups. The study is 1077  
designed to obtain a primary safety profile on patients in this age -group.  1078  
This study is an early feasibility study that  will test the  safety  of t:sli m X2 with Control -IQ 1079  
Technology in an outpatient s etting. These studies would generate up to 75 days of closed -loop 1080  
data. This sample size allows for subject withdrawal.  1081  
13.2 Statistical Hypotheses  1082  
13.2.1  Primary Outcome  1083  
Number of subject with less than 6% time belo w 70mg/dL and less than 40% time above 1084  
180mg/dL.  1085  
13.2.2  Secondary Outcome  1086  
1. % time spent <70 mg/dl, <60mg/dl, <54mg/dL, and <50mg/dL  1087  
2. % time spent >180mg/dl, and >250mg/dl, >300 mg/dl  1088  
3. % time spent between 70 -180mg/dl  1089  
4. % time spent between 70 -150mg/dl  1090  
5. Number of hypoglycemia below 70 mg/dL  1091  
6. Number of carbohydrate treatments, as well as total amount of carbohydrates used for  1092  
treatments.  1093  
7. Time spent in closed loop  1094  
8. Time with available CGM  1095  
9. Number of subject with more than 70% time in 70 -180mg/dL range with less than 4%  1096  
time below 70mg/dL  1097  
13.2.3  Success Criteria  / Goal 1098  
As a general rule, a session will be considered useful for data analysis if the subject completes 1099  
close to 80% of the active study protocol. Sessions are considered separate: (i) Supervised 1100  
Phase=complete at least 38 hours of AP; (ii) at home use=complete at least 56 hours of AP.  1101  
The primary goal will be considered met is the primary outcome is achieved for 65% or more of 1102  
the subjects . 1103  
13.2.4  Stati stical Analysis Plan 1104  
Proportions of subject matching primary criteria will be computed and directly compared to 65% 1105  
(considered baseline). Further analysis will be performed using a chi2 test of goodness of fit. Based 1106  
on prior data in 6 -12 year olds we anticipate an possible effect size of 0.64, which would allow to 1107  
detect a difference with 70% power considering our samp le size.  1108  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 47 of 50 Overall outcomes will be compared to the normative data below (values derived from the analysis 1109  
of 30 6 -12 year old T1D subjects using pumps and CGM and rounded for ease of use):  1110  
 Baseline  
 mean  std 
% time below 50mg/dL  0.5%  0.5%  
% time below 54mg/dL  1% 0.8%  
% time below 60mg/dL  2% 1% 
% time below 70 mg/dL  4% 2.5%  
% time between 70 -140mg/dL  40% 9% 
% time between 70 -180mg/dL  60% 9% 
% time above 180mg/dL  35% 9% 
% time above 250mg/dL  11% 5% 
% time above 300mg/dL  4% 3% 
     
Average CGM [mg/dL]  162.0  15.0 
This analysis will be performed using a single group one sided t -test for mean comparison for 1111  
outcomes that can be assumed normally distributed and One -Sample Wilcoxon Signed Rank test 1112  
for median comparison for the others, this analysis  is not powered.  1113  
Secondary outcomes will be reported for the entire period and for the supervised and home phases 1114  
separately. Outcomes by phase will be compared to each other to assess possible loss of 1115  
performances during the transition at home. For this p urpose, McNemar’s tests will be used to 1116  
compare the supervised phase to the home phase for the primary outcome and secondary outcome 1117  
# 6, 7, and 8. All other outcomes will be analyzed using repeated measure ANOVA. Significance 1118  
of 0.05 will be used.  1119  
This an alysis is not powered.  1120  
CLINCAL  PROTOCOL  
 
 
Control -IQ Preschoolers – 30-Aug-2019         Page 48 of 50 Chapter 14:    DATA COLLECTION AND MONITORING  1121  
14.1 Case Report Forms and Device Data  1122  
The study data are collected through a combination of case report forms (electronic and paper) and 1123  
electronic device data files obtained from the software and individual hardware components.  1124  
These electronic device files and electronic CRFs are considered the primary source 1125  
documentation.  1126  
When data are directly collected in electronic case report forms, this will be considered the source 1127  
data.  Rec ords will be maintained in accordance with ICH E6 and institutional regulatory 1128  
requirements for the protection of confidentiality of participants.  1129  
14.2 Study Records Retention  1130  
Study documents should be retained for a minimum of 2 years after the last approval o f a marketing 1131  
application in an ICH region and until there are no pending or contemplated marketing applications 1132  
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical 1133  
development of the investigational product .  These documents should be retained for a longer 1134  
period, however, if required by local regulations.  No records will be destroyed without the written 1135  
consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 1136  
investigat or when these documents no longer need to be retained.  1137  
14.3 Protocol Deviations  1138  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1139  
(GCP ), or procedure requirements.  The noncompliance may be either on the part of the participant, 1140  
the investigator, or the study site staff.  As a result of deviations, corrective actions may be 1141  
developed by the  site and implemented as appropriate .  Major d eviations will be reported to the 1142  
IRB-HSR within 7 calendar days of when the study team becomes aware of the event. 1143  
UNIVERSITY OF VIRGINIA  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 49 of 50 Chapter 15:    ETHICS /PROTECTION OF HUMAN PARTICIPANTS  1144  
15.1 Ethical Standard  1145  
The investigator will ensure that this study is conducted in full conformity with R egulations for 1146  
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1147  
CFR Part 56, and/or the ICH E6.  1148  
15.2 Institutional Review Boards  1149  
The protocol, informed consent form(s), recruitment materials, and all participant ma terials will 1150  
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 1151  
form must be obtained before any participant is enrolled.  Any amendment to the protocol will 1152  
require review and approval by the IRB before the cha nges are implemented to the study.  All 1153  
changes to the consent form will be IRB approved; a determination will be made regarding whether 1154  
previously consented participants need to be re -consented.  1155  
15.3 Informed Consent Process  1156  
15.3.1  Consent Procedures and Documentatio n 1157  
Informed consent is a process that is initiated prior to an individual’s agreement  to participate in 1158  
the study and continues throughout the individual’s study participation.  Extensive discussion of 1159  
risks and possible benefits of participation will be pr ovided.  Consent forms will be IRB approved 1160  
and the participant will be asked to read and review the document.  The investigator  or their 1161  
delegate  will explain the research study to the parent/guardian(s) and answer any questions that 1162  
may arise.  All parti cipants will receive a verbal explanation in terms suited to their comprehension 1163  
of the purposes, procedures, and potential risks of the study and of their rights as research 1164  
participants.  Parent/guardian(s) will have the opportunity to carefully review t he written consent 1165  
form and ask questions prior to signing.  1166  
The parent/guardian(s) will sign the informed consent document prior to any procedures being 1167  
done specifically for the study.  The parent/guardian(s) may withdraw their child’s consent at any 1168  
time throughout the course of the trial.  A copy of the informed consent document will be given to 1169  
the parent/guardian(s) for their records.  The rights and welfare of the participants will be protected 1170  
by emphasizing to them that the quality of their medical care will not be adversely affected if they 1171  
decline to participate in this study.  1172  
A child participant is considered enrolled when the informed consent form has been signed.  1173  
15.3.2  Participant and Data Confidentiality  1174  
The study monitor , representatives of the IRB or device company supplying study product may 1175  
inspect all documents and records required to be maintained by the investigator, including but not 1176  
limited to, medical records (office, clinic, or hospital) for the participants in this study.   1177  
UNIVERSITY OF VIRGINIA  
 
Control -IQ Preschoolers – 30-Aug-2019         Page 50 of 50 The study participant’s contact information will be securely stored at the clinical  site for internal 1178  
use during the study.  At the end of the study, all records will continue to be kept in a secure 1179  
location for as long a period as dictated b y local IRB and Institutional regulations.  1180  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, 1181  
will be transmitted to and stored at the University of Virginia Center for Diabetes Technology.  1182  
This will n ot include the participant’s contact or identifying information.  Rather, individual 1183  
participants and their research data will be identified by a unique study identification number.  The 1184  
study data entry and study management systems used by research staff  will be secured and 1185  
password protected.  At the end of the study, all study databases may be de -identified and archived 1186  
at the University of Virginia Center for Diabetes Technolo gy.   1187  